Big Pharma Chooses Philadelphia Summit to discuss Business Intelligence

eyeforpharmaAn unprecedented Pharma speaker line-up will headline this 2008 flagship event. Attracting its usual mix of senior-level pharma and biotech delegates, the event will act as a platform for the most innovative speakers in pharma and a forum for debate to discuss how to effectively communicate intelligence to make commercial decisions faster, smarter and better. Attendees from all Pharma companies and service providers focusing on this area are registered to gather on October 1-2 for conference sessions, networking, and nightly socializing functions.

The BI and CI function has never been more integral to the future of pharma as companies seek the most innovative ways to assess and beat the competition. In order to recapture the days of double digit growth, pharma take a ore streamlined approach to competitive intelligence and business analysis and interpret and communicate this intelligence to aid strategic decision-making, says Binyah Kesselly, Director of Enterprise Improvement and Business Excellence at Johnson & Johnson.

The two day information and networking extravaganza will allow the executives to meet among themselves to further set forth better decision-making processes earlier in clinical development to make more effective pipeline and product decisions and ensure that new product launches are based on the optimal intelligence and the best commercial interest.

Highlights of this conference include the following:

  • The Only Annual Conference with all of the top 10 Pharma Companies Present
  • Panel of Past SCIP Presidents
  • Large Exhibition Of BI, CI and other Business Analysis Service Providers
  • Expanded Agenda To Attract Market Research And Business Analysis Executives
  • Pre-event Online Social Network – over 300 members already!

The speaking faculty includes a pharmaceutical industry "Who's Who" list of CI, BI and Business Analysis professionals from pharma & biotech include the following companies: Pfizer, Johnson & Johnson, sanofi-aventis, AstraZeneca, Novartis, Alcon Laboratories, Biovail, Daiichi Sankyo, Ortho McNeil Pharmaceutical, Shire Laboratories, ThermoFisher Diagnostics, EFP Markets...

For further information, please visit:
http://www.eyeforpharma.com/BizIntel08

About eyeforpharma
eyeforpharma is a leading global source of information for the pharmaceutical industry. Our reputation has been built on quality, in-depth conferences that have distinguished themselves from competitors by the depth and breadth of research we put into each conference to ensure it is covering the hottest and most pertinent issues of the industry. Months are spent talking directly to senior executives in the industry, as well as relevant consultants and journalists and well respected solutions providers. For more information, please visit www.eyeforpharma.com.

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech advance COVID-19 vaccine strat…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to...

New needle-free nasal vaccine shows promise for CO…

New research shows that a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection. The findings were published in mB...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Disparities in United States COVID-19 vaccine dist…

When reports showed COVID-19 vaccination rates were lower among racial/ethnic minority groups, most discussions focused on mistrust and misinformation among these populat...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

GSK signs agreement to support pandemic preparedne…

GSK plc (LSE/NYSE: GSK) announced it had signed a framework contract with the European Commission's (EC) Health Emergency Preparedness and Response Authority (HERA) for t...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

Scientists develop new biomimetic formulation for …

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. New and effective approaches for GBM treatment are therefore ...